Online citations, reference lists, and bibliographies.
← Back to Search

Mesoporous Silica Nanoparticles For Treating Spinal Cord Injury

Désirée White-Schenk, R. Shi, J. Leary
Published 2013 · Chemistry, Engineering

Cite This
Download PDF
Analyze on Scholarcy
Share
An estimated 12,000 new cases of spinal cord injury (SCI) occur every year in the United States. A small oxidative molecule responsible for secondary injury, acrolein, is an important target in SCI. Acrolein attacks essential proteins and lipids, creating a feed-forward loop of oxidative stress in both the primary injury area and the surrounding areas. A small molecule used and FDA-approved for hypertension, hydralazine, has been found to "scavenge" acrolein after injury, but its delivery and short half-life, as well as its hypertension effects, hinder its application for SCI. Nanomedical systems broaden the range of therapeutic availability and efficacy over conventional medicine. They allow for targeted delivery of therapeutic molecules to tissues of interest, reducing side effects of untargeted therapies in unwanted areas. Nanoparticles made from silica form porous networks that can carry therapeutic molecules throughout the body. To attenuate the acrolein cascade and improve therapeutic availability, we have used a one-step, modified Stober method to synthesize two types of silica nanoparticles. Both particles are “stealth-coated” with poly(ethylene) glycol (PEG) (to minimize interactions with the immune system and to increase circulation time), which is also a therapeutic agent for SCI by facilitating membrane repair. One nanoparticle type contains an amine-terminal PEG (SiNP-mPEG-Am) and the other possesses a terminal hydrazide group (SiNP-mPEG-Hz). The former allows for exploration of hydralazine delivery, loading, and controlled release. The latter group has the ability to react with acrolein, allowing the nanoparticle to scavenge directly. The nanoparticles have been characterized and are being explored using neuronal PC-12 cells in vitro, demonstrating the potential of novel silica nanoparticles for use in attenuating secondary injury after SCI.
This paper references
10.1111/j.1471-4159.2009.06395.x
Acrolein scavenging: a potential novel mechanism of attenuating oxidative stress following spinal cord injury
K. Hamann (2009)
10.1021/LA052797J
Surface modification of silica nanoparticles to reduce aggregation and nonspecific binding.
R. Bagwe (2006)
10.1021/BM030021W
Synthesis of a chitosan-dendrimer hybrid and its biodegradation.
H. Sashiwa (2003)
10.1016/j.biomaterials.2009.10.046
The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses.
Q. He (2010)
10.1038/nmat2398
Biodegradable luminescent porous silicon nanoparticles for in vivo applications.
J. Park (2009)
10.1002/jnr.20863
Acrolein‐mediated mechanisms of neuronal death
Peishan Liu-Snyder (2006)
10.1038/sj.sc.3101158
Incidence rates and populations at risk for spinal cord injury: A regional study
DA Burke (2001)
10.1117/12.589422
Biosensor-controlled gene therapy/drug delivery with nanoparticles for nanomedicine
T. Prow (2005)
Synthesis and characterisation of silica nanoparticles bearing different functional groups obtained via a two - stage method , ” physica status solidi ( c ) 7 , 2692 – 2696 (
G. Berriozabal (2010)
10.1021/LA061879K
Silica- and alkoxysilane-coated ultrasmall superparamagnetic iron oxide particles: a promising tool to label cells for magnetic resonance imaging.
C. Zhang (2007)
10.1016/S0306-4522(02)00457-8
Acrolein inflicts axonal membrane disruption and conduction loss in isolated guinea-pig spinal cord
R. Shi (2002)
10.1016/j.neuint.2003.09.006
Acrolein induces axolemmal disruption, oxidative stress, and mitochondrial impairment in spinal cord tissue
J. Luo (2004)
10.1016/0300-483X(80)90014-1
Decrease of reduced glutathione in isolated rat hepatocytes caused by acrolein, acrylonitrile, and the thermal degradation products of styrene copolymers.
A. Zitting (1980)
10.1016/S0168-3659(01)00530-2
PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties.
K. Avgoustakis (2002)
10.1002/jnr.20862
Hydralazine rescues PC12 cells from acrolein‐mediated death
Peishan Liu-Snyder (2006)
10.2147/IJN.S25071
Amorphous silica nanoparticles trigger nitric oxide/peroxynitrite imbalance in human endothelial cells: inflammatory and cytotoxic effects
J. Corbalan (2011)
10.1242/jeb.035162
Chitosan produces potent neuroprotection and physiological recovery following traumatic spinal cord injury
Youngnam Cho (2010)
10.1111/j.1471-4159.2007.05002.x
Hydralazine inhibits compression and acrolein‐mediated injuries in ex vivo spinal cord
K. Hamann (2008)
10.1007/S00289-009-0089-0
Preparation of poly(ethylene glycol)-grafted silica nanoparticles using a facile esterification condensation method
L. Feng (2009)
10.1016/j.neuroscience.2010.11.018
Anti-acrolein treatment improves behavioral outcome and alleviates myelin damage in experimental autoimmune enchephalomyelitis mouse
G. Leung (2011)
10.2217/17435889.3.4.507
Functionalized mesoporous silica nanoparticle-based drug delivery system to rescue acrolein-mediated cell death.
Youngnam Cho (2008)
10.1021/ja3049783
Ultrasmall sub-10 nm near-infrared fluorescent mesoporous silica nanoparticles.
K. Ma (2012)
10.1111/j.1471-4159.2008.05622.x
Critical role of acrolein in secondary injury following ex vivo spinal cord trauma
K. Hamann (2008)
10.1016/J.JCONREL.2006.06.017
PEG-modified gold nanorods with a stealth character for in vivo applications.
T. Niidome (2006)
10.1007/s11064-005-2602-7
Accumulation of Acrolein–Protein Adducts after Traumatic Spinal Cord Injury
J. Luo (2005)
10.1002/PSSC.200983837
Synthesis and characterisation of silica nanoparticles bearing different functional groups obtained via a two‐stage method
Gemma Berriozabal (2010)
10.1074/jbc.273.26.16058
Acrolein Is a Product of Lipid Peroxidation Reaction
K. Uchida (1998)
10.1002/smll.200800461
Size-dependent cytotoxicity of monodisperse silica nanoparticles in human endothelial cells.
D. Napierska (2009)
10.1002/smll.201001459
In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation.
Q. He (2011)
10.1016/S0168-3659(99)00063-2
Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting.
M. Peracchia (1999)
10.1002/JBM.A.10057
Room-temperature preparation and characterization of poly (ethylene glycol)-coated silica nanoparticles for biomedical applications.
Hao Xu (2003)
10.1016/J.JCIS.2007.02.024
Synthesis of poly(ethylene glycol) (PEG)-grafted colloidal silica particles with improved stability in aqueous solvents.
Zhenkun Zhang (2007)
10.1242/jeb.02756
Neuroprotection from secondary injury by polyethylene glycol requires its internalization
Peishan Liu-Snyder (2007)
10.1021/CM990661Z
Dilute solution routes to various controllable morphologies of MCM-41 silica with a basic medium
Qiang Cai (2001)
10.1021/LA049137J
Optimization of dye-doped silica nanoparticles prepared using a reverse microemulsion method.
R. Bagwe (2004)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar